Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
716 (USA) · Dr. Ito
consented 2014-01-22
AEs
1
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-05-11 (study day 110.0); relationship: PROBABLE
Data queries
No data queries.